KANSL3: A Non-Functional RNA-Protein Hybrid Regulating Neurotransmission

Target Name: KANSL3

NCBI ID: G55683

KANSL3

KANSL3: A Non-Functional RNA-Protein Hybrid Regulating Neurotransmission

The KANSL3 protein, also known as KAT8 regulatory NSL complex subunit 3 (isoform 1), is a protein that plays a critical role in regulating neurotransmitter release in the nervous system. The KanSL3 gene is located on chromosome 6 and encodes a protein that belongs to the neurotransmitter-stimulated ion channels (NSL) family. This family is characterized by the presence of a highly conserved transmembrane region, a putative ion channel domain, and a C-terminal region that is involved in protein-protein interactions.

KANSL3 is a non-functional RNA-protein hybrid that is predominantly expressed in the brain and nervous system. It is a key regulator of neurotransmitter release and has been implicated in a number of neurological and psychiatric disorders. The most well-studied function of KANSL3 is its role in the regulation of synaptic plasticity, which is the ability of the nervous system to change and adapt over time.

One of the key functions of KANSL3 is its role in the regulation of the neurotransmitter release that occurs during synaptic plasticity. KANSL3 has been shown to play a critical role in the regulation of the neurotransmitter release that occurs during the early stages of synaptic plasticity, when new neurons are formed or the connections between existing neurons are modified.

KANSL3 is also involved in the regulation of the neurotransmitter release that occurs during the later stages of synaptic plasticity, when the connections between existing neurons are strengthened or the brain is exposed to new stimuli. This is thought to happen by modulating the activity of other genes that are involved in neurotransmitter release, such as the neurotransmitter itself or the ion channels that are involved in neurotransmission.

In addition to its role in synaptic plasticity, KANSL3 is also involved in the regulation of other processes in the nervous system. For example, it has been shown to play a critical role in the regulation of ion traffic in the brain, which is the movement of ions through the blood-brain barrier and into the cells of the brain. This is thought to be important for the proper functioning of the brain and is a potential target for new therapies.

KANSL3 is also involved in the regulation of the growth and development of the nervous system. For example, it has been shown to play a critical role in the regulation of the neurogenesis of new neurons, which is the process by which new neurons are formed in the nervous system. This is thought to be important for the development and maintenance of the nervous system and is a potential target for new therapies.

In conclusion, KANSL3 is a protein that plays a critical role in regulating neurotransmitter release in the nervous system. Its function in synaptic plasticity and other processes in the nervous system makes it a potential drug target or biomarker for a variety of neurological and psychiatric disorders. Further research is needed to fully understand the role of KANSL3 in the regulation of neurotransmission and to develop new treatments based on its properties.

Protein Name: KAT8 Regulatory NSL Complex Subunit 3

Functions: As part of the NSL complex it is involved in acetylation of nucleosomal histone H4 on several lysine residues and therefore may be involved in the regulation of transcription

The "KANSL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KANSL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets